Shares of Catalent Inc (NYSE:CTLT) fell 5.7% on Friday . The company traded as low as $40.59 and last traded at $40.67. 739,815 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 899,777 shares. The stock had previously closed at $43.12.
A number of research firms have recently weighed in on CTLT. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Morgan Stanley set a $46.00 price objective on Catalent and gave the stock a “buy” rating in a research report on Monday, December 3rd. TheStreet raised Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, February 6th. Finally, First Analysis reissued an “outperform” rating and issued a $49.00 price objective on shares of Catalent in a research report on Tuesday, March 5th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $47.86.
The company has a debt-to-equity ratio of 1.36, a current ratio of 2.08 and a quick ratio of 1.63. The stock has a market capitalization of $6.18 billion, a price-to-earnings ratio of 25.58, a price-to-earnings-growth ratio of 2.33 and a beta of 1.70.
In other Catalent news, SVP William Downie sold 7,315 shares of Catalent stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $42.00, for a total transaction of $307,230.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Lance Miyamoto sold 43,619 shares of Catalent stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $42.49, for a total value of $1,853,371.31. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Nordea Investment Management AB lifted its position in Catalent by 36.0% during the 3rd quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock worth $4,997,000 after acquiring an additional 29,008 shares during the period. JPMorgan Chase & Co. lifted its position in Catalent by 29.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after acquiring an additional 1,819,020 shares during the period. First Bank & Trust lifted its holdings in shares of Catalent by 13.9% in the 4th quarter. First Bank & Trust now owns 4,600 shares of the company’s stock valued at $143,000 after buying an additional 563 shares during the period. Utah Retirement Systems lifted its holdings in shares of Catalent by 9.4% in the 3rd quarter. Utah Retirement Systems now owns 26,800 shares of the company’s stock valued at $1,220,000 after buying an additional 2,300 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Catalent by 234.5% in the 3rd quarter. AQR Capital Management LLC now owns 82,106 shares of the company’s stock valued at $3,740,000 after buying an additional 57,562 shares during the period. 98.79% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Catalent (CTLT) Shares Down 5.7%” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2019/03/23/catalent-ctlt-shares-down-5-7.html.
Catalent Company Profile (NYSE:CTLT)
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: What is the outlook for the FAANG stocks?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.